What a bloodbath that was. SRPT, ARIA, CLSN - all very real reminders that even the most promising biotechs present a very real risk to investors. But that's why we're here -  no risk, no reward. And I do feel more confident knowing we have 3 very promising drug candidates, and are not just a one trick pony.